Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind placebo-controlled exploratory trial

Marlies Antlanger; Oliver Domenig; Christopher C. Kaltenecker; J. Kovarik; Manfred Hecking; Marko Poglitsch; Chantal Kopecky; Markus Säemann; Elisabeth Schwaiger; Martin M. Müller; Vincent Rathkolb

doi:10.1111/dom.14639

Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind placebo-controlled exploratory trial

Marlies Antlanger
, Oliver Domenig
, Christopher C. Kaltenecker
, J. Kovarik
, Manfred Hecking
, Marko Poglitsch
, Chantal Kopecky
, Markus Säemann
, Elisabeth Schwaiger
, Martin M. Müller
, Vincent Rathkolb

Department of Internal Medicine 2 - Gastroenterology and Hepatology, Endocrinology and Metabolism, Nephrology, Rheumatology

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	816-826
Number of pages	11
Journal	Diabetes, Obesity and Metabolism
Volume	24
Issue number	5
DOIs	https://doi.org/10.1111/dom.14639
Publication status	Published - May 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Fields of science

302016 Gastroenterology
302025 Hepatology
302030 Internal medicine

Access to Document

10.1111/dom.14639

Cite this

Antlanger, M., Domenig, O., Kaltenecker, C. C., Kovarik, J., Hecking, M., Poglitsch, M., Kopecky, C., Säemann, M., Schwaiger, E., Müller, M. M., & Rathkolb, V. (2022). Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind placebo-controlled exploratory trial. Diabetes, Obesity and Metabolism, 24(5), 816-826. https://doi.org/10.1111/dom.14639

Antlanger, Marlies ; Domenig, Oliver ; Kaltenecker, Christopher C. et al. / Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind placebo-controlled exploratory trial. In: Diabetes, Obesity and Metabolism. 2022 ; Vol. 24, No. 5. pp. 816-826.

@article{9b3ce648c0164d7780a5f26ea0cc751a,

title = "Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind placebo-controlled exploratory trial",

author = "Marlies Antlanger and Oliver Domenig and Kaltenecker, \{Christopher C.\} and J. Kovarik and Manfred Hecking and Marko Poglitsch and Chantal Kopecky and Markus S{\"a}emann and Elisabeth Schwaiger and M{\"u}ller, \{Martin M.\} and Vincent Rathkolb",

year = "2022",

month = may,

doi = "10.1111/dom.14639",

language = "English",

volume = "24",

pages = "816--826",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "Wiley",

number = "5",

}

Antlanger, M, Domenig, O, Kaltenecker, CC, Kovarik, J, Hecking, M, Poglitsch, M, Kopecky, C, Säemann, M, Schwaiger, E, Müller, MM & Rathkolb, V 2022, 'Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind placebo-controlled exploratory trial', Diabetes, Obesity and Metabolism, vol. 24, no. 5, pp. 816-826. https://doi.org/10.1111/dom.14639

Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind placebo-controlled exploratory trial. / Antlanger, Marlies; Domenig, Oliver; Kaltenecker, Christopher C. et al.
In: Diabetes, Obesity and Metabolism, Vol. 24, No. 5, 05.2022, p. 816-826.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind placebo-controlled exploratory trial

AU - Antlanger, Marlies

AU - Domenig, Oliver

AU - Kaltenecker, Christopher C.

AU - Kovarik, J.

AU - Hecking, Manfred

AU - Poglitsch, Marko

AU - Kopecky, Chantal

AU - Säemann, Markus

AU - Schwaiger, Elisabeth

AU - Müller, Martin M.

AU - Rathkolb, Vincent

PY - 2022/5

Y1 - 2022/5

UR - https://www.scopus.com/pages/publications/85123589623

U2 - 10.1111/dom.14639

DO - 10.1111/dom.14639

M3 - Article

C2 - 34984822

SN - 1462-8902

VL - 24

SP - 816

EP - 826

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

IS - 5

ER -

Antlanger M, Domenig O, Kaltenecker CC, Kovarik J, Hecking M, Poglitsch M et al. Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind placebo-controlled exploratory trial. Diabetes, Obesity and Metabolism. 2022 May;24(5):816-826. doi: 10.1111/dom.14639

Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind placebo-controlled exploratory trial

UN SDGs

Fields of science

Access to Document

Other files and links

Cite this